Inhibikase Therapeutics Inc at Truist Securities Life Sciences Summit (April Series) Transcript
Good morning, everyone. I hope everyone can hear me. I'm not quite sure if we've lost everyone. Milton, are you on?
I am.
Okay. Great. So welcome, everyone to the Truist Life Sciences Summit Conference Call series. This morning, we have Inhibikase. Ticker, IKT. I'm very excited to share with you the story. And we have the CEO, Milton Werner to go through it a little bit.
Before we start, feel free to e-mail me with questions. But I have to read some disclosures. So one second. The call is arranged by Truist Securities Research for the use by institutional investors and issuer clients as defined by FINRA.
If you're not an institutional investor or an issuer, please disconnect at this time. For required disclosures, please see our website at Truist Securities, or our research equity research library.
So I'm excited to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |